Mistletoe therapy is a form of integrative cancer treatment in which extracts from European mistletoe (the same plant hung as a holiday decoration) are injected to stimulate the immune system and improve quality of life during cancer care. It is one of the most widely used complementary therapies in European oncology, though the U.S. Food and Drug Administration has not approved it for cancer or any other medical condition. The therapy is primarily used alongside conventional treatments like chemotherapy and radiation, not as a replacement for them.
How Mistletoe Extracts Work
Mistletoe extracts contain several biologically active compounds, but two groups do most of the heavy lifting: lectins and viscotoxins. Lectins are complex molecules that bind to the surface of cells and trigger biochemical changes inside them. Four distinct lectins have been identified in mistletoe, and one called ML-1 (or viscumin) appears to drive the majority of the biological effects. When researchers selectively removed ML-1 from mistletoe extracts in the lab, both the cancer-killing and immune-stimulating properties dropped significantly.
ML-1 works through a two-part structure. One chain binds to the surface of a target cell, while the other enters the cell and interferes with its ability to make proteins. This disruption triggers a self-destruct sequence called apoptosis. In lab studies, mistletoe extracts have restored the ability of radiation-resistant cancer cells to undergo this programmed death, suggesting the extracts may help overcome certain types of treatment resistance.
Viscotoxins, the other key group, are small proteins that kill cells directly and may also stimulate the immune system. Together with lectins and certain polysaccharides, they create what researchers describe as a synergistic effect, meaning the compounds working together produce stronger results than any single ingredient alone.
Effects on the Immune System
Beyond directly targeting cancer cells, mistletoe therapy acts as what’s formally classified as a biological response modifier: it changes how the immune system behaves. One well-documented effect is the activation of natural killer (NK) cells, a type of immune cell that patrols the body and destroys abnormal cells. A Phase I clinical trial of intravenous mistletoe found that it increased markers of NK cell activity and boosted the production of signaling molecules that recruit NK cells to tumor sites.
Mistletoe extracts also stimulate a specialized subset of immune cells that release toxic granules directly into cancer cells while producing inflammatory signals that alert the broader immune system. Fermented preparations trigger a chain of immune-visible changes on dying cancer cells, essentially flagging them so the immune system recognizes and remembers the threat. This process, called immunogenic cell death, is a goal of several modern immunotherapy approaches.
What Treatment Looks Like
Mistletoe therapy is typically administered by subcutaneous injection, similar to an insulin shot, two to three times per week. Doses usually start low and increase gradually based on how you respond, including the size of any local skin reaction at the injection site and changes in body temperature. Some physicians also adjust dosing based on immune markers measured through blood tests.
Treatment courses vary widely. In clinical studies, durations have ranged from three months to over a year. Some protocols run 15 to 24 weeks alongside chemotherapy, then continue for an additional two months afterward. Others extend to 60 weeks or longer. There is no single standardized protocol, and the approach depends on the type of cancer, the stage of treatment, and the practitioner’s philosophy.
Mistletoe extracts are also increasingly given intravenously, directly into tumors, or into body cavities, though these routes are considered off-label. The subcutaneous injection remains the standard method.
Different Preparations and Host Trees
Several commercial mistletoe preparations exist, including Iscador, Helixor, AbnobaVISCUM, and Iscucin. These are produced under pharmaceutical guidelines from anthroposophical medicine, a holistic medical tradition with roots in early 20th-century Europe. A separate category, phytotherapeutic preparations like Lektinol, are standardized to contain a specific amount of lectin and given at a fixed dose twice weekly.
One distinctive feature of mistletoe therapy is that the host tree matters. Mistletoe is a semi-parasitic plant that grows on many tree species, and extracts from mistletoe harvested from oak trees differ in composition from those harvested from apple or pine trees. Preparations are often labeled by host tree: Qu for oak (Quercus), M for apple (Malus), P for pine (Pinus). The concentrations of lectins, viscotoxins, and other compounds shift depending on the host tree, the time of year the plant is harvested, and the manufacturing process.
Quality of Life Benefits
The strongest clinical evidence for mistletoe therapy centers on quality of life rather than tumor shrinkage. A systematic review and meta-analysis pooling data from multiple controlled trials found statistically significant improvements in nausea and vomiting for patients receiving mistletoe extracts compared to controls. Improvements in emotional functioning and fatigue trended positive but did not reach statistical significance, leaving some uncertainty about how consistently these benefits appear across different patient populations.
Quality-of-life assessments in studies typically began showing measurable changes within four to six weeks of starting treatment, with ongoing monitoring every few weeks throughout chemotherapy cycles. For many patients, the primary appeal of mistletoe therapy is the potential to feel better during an otherwise grueling treatment course.
Survival Data
A meta-analysis of retrospective studies examining cancer survival found a pooled hazard ratio of 0.59 in favor of patients who received mistletoe treatment, with a 95% confidence interval of 0.50 to 0.70. In practical terms, this suggests that mistletoe-treated patients in these studies had roughly a 40% lower risk of death compared to control groups. However, these were retrospective studies, which are more vulnerable to selection bias than randomized trials. Patients who seek out mistletoe therapy may differ from those who don’t in ways that independently affect survival, such as overall health, motivation, or access to care.
Regulatory Status and Access
In Germany, Switzerland, and several other European countries, mistletoe therapy is a mainstream part of integrative oncology. It is prescribed by physicians and, in some cases, covered by health insurance. Tens of thousands of cancer patients in Europe receive it annually.
In the United States, the picture is very different. The FDA has not approved mistletoe extracts as a treatment for cancer or any other condition. Mistletoe preparations cannot be legally marketed as drugs, and access is limited to certain integrative medicine clinics, naturopathic practices, or clinical trials. Some practitioners import European preparations for use under individual patient protocols. The gap between European integration and American regulatory caution reflects differences in how the two systems evaluate botanical medicines, not necessarily a disagreement about the underlying science.
Side Effects
The most common side effect is a local reaction at the injection site: redness, swelling, and mild itching that typically resolves on its own. This reaction is actually considered a sign that the immune system is responding, and practitioners use its size to guide dosing decisions. Low-grade fever can also occur, particularly in the early stages of treatment as doses are being increased. Serious adverse events are rare in the published literature, but allergic reactions are possible, especially in people with known sensitivities to the plant.